Liberty Wealth Management LLC Has $51,000 Stock Holdings in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)

Liberty Wealth Management LLC trimmed its holdings in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) by 93.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,666 shares of the biotechnology company’s stock after selling 317,484 shares during the period. Liberty Wealth Management LLC’s holdings in Brainstorm Cell Therapeutics were worth $51,000 at the end of the most recent quarter.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on shares of Brainstorm Cell Therapeutics in a research note on Monday. They issued a “hold” rating for the company.

Brainstorm Cell Therapeutics Stock Performance

Shares of NASDAQ:BCLI opened at $1.57 on Thursday. Brainstorm Cell Therapeutics Inc. has a 52-week low of $1.05 and a 52-week high of $11.89. The company has a market capitalization of $8.95 million, a P/E ratio of -0.33 and a beta of 0.74. The company has a 50-day simple moving average of $1.87 and a 200 day simple moving average of $2.26.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.